Stacy Kish

Pivotal clinical trials in Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis are expected to read out this fall. Here’s a closer look.
The current workforce lacks the skills to move these biological treatments through the regulatory and production pipeline, a new report finds.